PUBLIC COMPANY
save$STOKStoke Therapeutics, Inc.
$STOK25.88+1.49%Bedford, MA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
- phase2An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
- phase2An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Stoke Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaRare Disease 2CNS / Neuroscience 1
News
no news has mentioned this company yet
Data sources
last refreshed 51m ago
Found something off?
comments(0)
5-min edit window · permanent after that